TITAN trial; shifting focus from hormone-refractory to hormone-sensitive prostate cancer
[1] It included CSPC patients with distant metastatic disease measured by ≥1 lesion on bone scan, with or without visceral/lymph node involvement and ECOG performance status of 0–1. CHAARTED/STAMPEDE (arm C/E), GETUG-AFU15, and subsequent meta-analysis established ADT + docetaxel as a standard of ca...
Saved in:
Published in | Indian journal of urology Vol. 36; no. 2; pp. 144 - 145 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
Vellore
Wolters Kluwer India Pvt. Ltd
01.04.2020
Medknow Publications & Media Pvt. Ltd Wolters Kluwer - Medknow Wolters Kluwer Medknow Publications |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | [1] It included CSPC patients with distant metastatic disease measured by ≥1 lesion on bone scan, with or without visceral/lymph node involvement and ECOG performance status of 0–1. CHAARTED/STAMPEDE (arm C/E), GETUG-AFU15, and subsequent meta-analysis established ADT + docetaxel as a standard of care (SOC) for high-volume mCSPC with good performance status and LATITUDE/STAMPEDE arm G, established ADT + abiraterone acetate and prednisone as a SOC for mCSPC, regardless of the disease volume status and performance status. [...]ADT + docetaxel should be preferred for men with good performance status, who have high-volume disease, desire shorter total treatment time, or have concerns of prescription drug costs, while ADT + abiraterone should be considered for men regardless of disease volume, who desire to avoid possible chemotherapy toxicity, or who want to minimize facility visits for docetaxel administration. [5] Again, during the preclinical development in animal model, apalutamide as compared to enzalutamide showed a steady-state plasma concentration 2–4-fold lower for the equivalent doses, whereas inter-tumoral level was roughly equivalent, with a greater antitumor activity at a lower dose and higher tumor/plasma ratio. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0970-1591 1998-3824 |
DOI: | 10.4103/iju.IJU_315_19 |